TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. ( (JP:4882) ) has provided an announcement.
Perseus Proteomics Inc. reported non-operating income, expenses, and extraordinary losses in the first nine months of the fiscal year ending March 2025. The company experienced gains from foreign exchange, outsourcing services, and interest, but also incurred costs related to capital increase and share issuance. A significant impairment loss on non-current assets was recorded, impacting the financial results for the third quarter, as announced.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates within the biotechnology sector, focusing on the development and commercialization of proteomics-based products and services. The company’s market focus includes leveraging advanced technologies for therapeutic and diagnostic applications.
YTD Price Performance: 3.38%
Average Trading Volume: 871,891
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen8.56B
For detailed information about 4882 stock, go to TipRanks’ Stock Analysis page.